New York, Jan. 09, 2018 -- According to the latest market report published by Persistence Market Research, titled “Nocturia Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026),” the global nocturia market is expected to expand at a CAGR of 7.5% during the forecast period 2017–2026. In 2017, the global market was valued at around US$ 2,500 Mn and is estimated to reach a valuation higher than US$ 4.5 Bn by the end of the forecast period.
Global Nocturia Market: Segmentation Forecast
The global nocturia market is segmented on the basis of indication type, drug type, distribution channel and region.
On the basis of indication type, the market is segmented into mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria and global polyuria. The low nocturnal bladder capacity segment is estimated to be the largest with a high market value and is projected to grow at a significant CAGR throughout the period of forecast. The nocturnal polyuria segment is projected to be the fastest growing and is expected to register a CAGR of 7.8% during the forecast period.
Global Nocturia Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/nocturia-market.asp
Based on drug type the market is segmented as anticholinergic drugs, desmopressin, antibiotics, antispasmodic and others. Desmopressin segment is poised to dominate the global market from a market value perspective. This segment reflected a market share of 31.6% in 2017, however it is expected to lose BPS by the end of the forecasted year.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. Hospital pharmacies is expected to hold major market share and registering CAGR of 8.1% in terms of value, over the forecast period owing to the increasing focus of availability. The online pharmacies segment is expected to gain high traction in the coming years and is projected to grow at a high CAGR of 8.4% during the period of forecast.
Request Sample Report@ https://www.persistencemarketresearch.com/samples/20806
On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia-Pacific, and the MEA. North America region led the nocturia market since past years and is likely to continue to dominate the overall market due to higher awareness and entry of players into the market by launching different products.
Companies are focusing on collaboration to develop new more effective products. The product type segment of nocturia will be boosted by its higher response rate and increasing research activities for R&D leading to inorganic growth.
Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/market-research/nocturia-market/toc
The global nocturia market is highly fragmented owing to the presence of various companies such as
- Allergan, Inc.
- Urigen Pharmaceuticals
- Ferring Pharmaceuticals
- Glenmark Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- AA Pharma Inc.
- Avadel Pharmaceuticals plc
- Others
Get full Report Now @ https://www.persistencemarketresearch.com/checkout/20806
Persistence Market Research Overview
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Mr. Rohit Bhisey Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [email protected] PMR Latest News: https://www.persistencemarketresearch.com/news


Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Samsung Electronics Shares Jump on HBM4 Mass Production Report
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 



